Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US

References

• National Heart, Lung, and Blood Institute. Atrial Fibrillation: National Heart, Lung, and Blood Institute; 2019. [cited 12 May 2020]. Available from: https://www.nhlbi.nih.gov/health-topics/atrial-fibrillation
   Google Scholar
• Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854–906.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–1147.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920–2925.
   PubMed Web of Science ®Google Scholar
• Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34(14):1061–1067.
   PubMed Web of Science ®Google Scholar
• Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol. 2002;155(9):819–826.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–952.
   PubMed Web of Science ®Google Scholar
• Bordignon S, Chiara Corti M, Bilato C. Atrial fibrillation associated with heart failure, stroke and mortality. J Atr Fibrillation. 2012;5(1):467.
   PubMedGoogle Scholar
• Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10(14 Suppl):S451–S458.
   PubMed Web of Science ®Google Scholar
• Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011; 4(3):313–320.
   PubMed Web of Science ®Google Scholar
• Li X, Tse VC, Au-Doung LW, et al. The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review. Europace. 2017;19(6):937–947.
   PubMed Web of Science ®Google Scholar
• Chatterjee NA, Lubitz SA. Systemic Embolic Events (SEE) in Atrial Fibrillation: SEEing Embolic Risk More Clearly. Circulation. 2015;132(9):787–789.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Saraiva JFK. Stroke prevention with oral anticoagulants: summary of the evidence and efficacy measures as an aid to treatment choices. Cardiol Ther. 2018;7(1):15–24.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (London, England). 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Holster IL, Valkhoff VE, Kuipers EJ, et al. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013;145(1):105–112.e15.
   PubMed Web of Science ®Google Scholar
• Xarelto® (rivaroxaban) Highlights of Prescribing Information. Janssen Pharmaceuticals, Inc.; 2019. p. 1–19. [cited 12 May 2020]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf
   Google Scholar
• Eliquis® (apixaban) Highlights of Prescribing Information. Bristol-Myers Squibb Company; 2018. p. 1–15. Available from: https://packageinserts.bms.com/pi/pi_eliquis.pdf
   Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. Effect of apixaban versus warfarin use on health care resource utilization and costs among elderly patients with nonvalvular atrial fibrillation. JMCP. 2017;23(11):1191–1201.
   PubMed Web of Science ®Google Scholar
• Laliberte F, Cloutier M, Crivera C, et al. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther. 2015;32(3):216–227.
   PubMed Web of Science ®Google Scholar
• Laliberte F, Pilon D, Raut MK, et al. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014;30(8):1521–1528.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33(9):1595–1604.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Vo L, et al. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. J Med Econ. 2018;21(3):244–253.
   PubMed Web of Science ®Google Scholar
• Gupta K, Trocio J, Keshishian A, et al. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the U.S. Department of Defense Population. JMCP. 2018;24(11):1116–1127.
   PubMed Web of Science ®Google Scholar
• Lin J, Trocio J, Gupta K, et al. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. J Med Econ. 2017;20(9):952–961.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Trocio J, et al. A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the U.S. Medicare Population. JMCP. 2018;24(9):911–920.
   PubMed Web of Science ®Google Scholar
• Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17(12):1202–1217.
   PubMed Web of Science ®Google Scholar
• Mehta PA, Grocott-Mason R, Dubrey SW. Adherence to anticoagulation guidelines for atrial fibrillation: a district general hospital survey. Br J Cardiol. 2004;11:474–477.
   Google Scholar
• Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9(5):348–356.
   PubMed Web of Science ®Google Scholar
• Lion J, Malbon A, Henderson MG, et al. A comparison of hospital outpatient departments and private practice. Health Care Financ Rev. 1985;6(4):69–81.
   PubMedGoogle Scholar
• Franco L, Becattini C, Vanni S, et al. Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial. Blood Transfus. 2018;16(4):387–391.
   PubMed Web of Science ®Google Scholar
• Majidi SL, Guerrero CR, Burger KM, et al. Inpatient versus outpatient management of TIA or minor stroke: clinical outcome. J Vasc Interv Neurol. 2017;9(4):49–53.
   PubMedGoogle Scholar
• Hart RG, Pearce LA, Koudstaal PJ. Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. Stroke. 2004;35(4):948–951.
   PubMed Web of Science ®Google Scholar
• O’Brien EC, Holmes DN, Thomas L, et al. Therapeutic strategies following major, clinically relevant nonmajor, and nuisance bleeding in atrial fibrillation: findings from ORBIT-AF. J Am Heart Assoc. 2018;7(12):e006391.
   Web of Science ®Google Scholar
• McHorney CA, Peterson ED, Ashton V, et al. Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients. Curr Med Res Opin. 2019;35(4):653–660.
   PubMed Web of Science ®Google Scholar
• Stephenson JJ, Shinde MU, Kwong WJ, et al. Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy. PPA. 2018;12:105–117.
   Web of Science ®Google Scholar